AstraZeneca Fights Damages In Drug Pricing Suit

By Erin Marie Daly · August 7, 2007, 12:00 AM EDT

On the heels of a similar bid by Warrick Pharmaceuticals Corp., AstraZeneca Pharmaceuticals LP has rejected a request that it shell out treble damages to two classes in the average wholesale...

To view the full article, register now.

Try a seven day FREE Trial

Already a subscriber? Click here to login

Documents

Motion

Case Information

Case Title

Citizens for Consume, et al v. Abbott Laboratories,, et al

Case Number

Court

Massachusetts

Nature of Suit

Anti-Trust

Date Filed

December 19, 2001

Recent Articles By Erin

May 19, 2011
Genentech Sues Apotex Over Generic Valcyte
May 19, 2011
CORRECTED: Mylan's Inequitable Conduct Claim Axed In Vytorin IP Suit
May 18, 2011
Firms, Experts Allowed To Stay In AndroGel MDL
May 10, 2011
Pharmacies Attack $68B Pfizer-Wyeth Deal In 9th Circ.
May 03, 2011
2nd Circ. Rejects Nurses Review Of Class Cert. Denial
April 27, 2011
Genzyme Sues Over Endo's Bid To Sell Generic Renvela
April 27, 2011
Asahi, Actelion Throw Final Punches In Fasudil IP Row
April 20, 2011
Novartis Targets Teva Over Myfortic Patents
April 13, 2011
HGS Fires Round 2 At Genentech Over Lupus Drug IP
April 13, 2011
MetroPlus, HHC Evade State Claims In OT Action